Acute Lymphoblastic Leukaemia
Oncology·MeSH: Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prevalence
30.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| azd3632 | ASTRAZENECA PLC (AZN) |
Frequently asked questions
How many drugs are in development for Acute Lymphoblastic Leukaemia?
BioSniper tracks 1 drug in development for Acute Lymphoblastic Leukaemia across 1 company.
How many clinical trials target Acute Lymphoblastic Leukaemia?
There are 1 clinical trial targeting Acute Lymphoblastic Leukaemia tracked by BioSniper.
What is the prevalence of Acute Lymphoblastic Leukaemia?
The estimated prevalence of Acute Lymphoblastic Leukaemia is approximately 30.0 per 100,000 population.
Deep-dive into Acute Lymphoblastic Leukaemia
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis